Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues

Will Pfizer ($PFE) come back at AstraZeneca ($AZN)? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals. Now, sources are telling the Financial Times and CNBC that the collapse of AbbVie's ($ABBV) buyout of Ireland-based Shire ($SHPG) make another Pfizer bid unlikely. Unless the midterm elections go against President Obama, that is. Report | Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.